You are about to be redirected to a site intended for people with primary HLH or their caregivers.

You are being redirected to a third party website.

Sobi takes no responsibility for the content of this website.

  1. HOME
  2. About Gamifant
  3. Results

Gamifant® (emapalumab-lzsg) was proven to be effective in a clinical trial1

For patients with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.

result-img

63% overall response rate (ORR) with Gamifant1

(95% CI: 0.42, 0.81; P = 0.013)

  • ORR is defined as achievement of either complete or partial response in HLH improvement.1
  • Median time to response was 8 days and responses were generally maintained.2
  • Median duration of first response, defined as time from achievement of first response to loss of first response, was not reached.1

70% of patients (19/27) proceeded to HSCT1

chart-img

Gamifant was shown to neutralize IFNγ1,2

Gamifant was shown to neutralize IFNγ as measured by a rapid and sustained reduction in the plasma concentrations of CXCL9, a chemokine induced almost exclusively by IFNγ.

See how Gamifant works

PREVIOUS:

  1. About Gamifant
  2. Pivotal Trial

Next:

  1. About Gamifant
  2. Safety

Looking for more?

Primary hlh

Discover the storm

Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3-6

about gamifant

Target IFNγ

Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.1

dosing

DOsing & Administration

Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1

Access & Support

HOw to ACCESS gamifant

Download the Start Form now or contact Gamifant Patient Services at 833.597.6530.
Resources

Help through the storm

Here you’ll find tools and resources to help your patients and their families.